| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT01696825 Details | 2014-12-16 Interventional | 1 | 3 | Diazepam Metabolism, Dru… | - - | |||
| NCT00053911 Details | 2014-12-16 Interventional | 3 | - | Anastrozole Cyclophosphamid… Docetaxel Epirubicin Fluorouracil Goserelin Tamoxifen Breast Neoplasm… Breast Cancer | - - | |||
| NCT01721707 Details | 2014-12-11 Interventional | 3 | 0 | Brinzolamide Latanoprost Glaucoma Glaucoma, Open-… Hypertension Ocular Hyperten… Open Angle Glau… | withdrawn by industry - | |||
| NCT01721694 Details | 2014-12-11 Interventional | 3 | 0 | Azithromycin Loteprednol Eta… Blepharitis Communicable Di… Conjunctivitis Conjunctivitis,… Infections Inflammation Keratitis Infection Assoc… Ocular Inflamma… | withdrawn by industry - | |||
| NCT00678288 2007-005083-28 Details | 2014-12-11 Interventional | 2 | 16 | Interferons Sorafenib Carcinoma Carcinoma, Rena… | - The study was terminated early by the Sponsor due to low accrual. No efficacy analyses were performed. | |||
| NCT01519076 Details | 2014-12-10 Interventional | 1 | 7 | Coal Tar Ischemic Stroke Stroke | Sponsor Request - | |||
| NCT00660062 Details | 2014-12-09 Interventional | 4 | 47 | Citalopram Dexetimide Escitalopram Nortriptyline Depression Depressive Diso… Recurrence Major Depressio… | Slow inclusion - | |||
| NCT00511043 Details | 2014-12-09 Interventional | 2 | 20 | Vatalanib Lymphoma Lymphoma, Large… Lymphoma, Large… | Manufacturer stopped drug development - | |||
| NCT00510081 Details | 2014-12-09 Interventional | 3 | 0 | Calcium Jowls | The study was not executed. No subjects were enrolled. - | |||
| NCT00306137 2005-004689-18 Details | 2014-12-09 Interventional | 3 | 104 | Aprotinin Blood Loss, Sur… Esophageal Neop… | - - | |||
| NCT01953445 Details | 2014-12-08 Interventional | 2 | 0 | Paclitaxel Breast Neoplasm… | The study sponsor found the trial to be not viable. - | |||
| NCT01291784 Details | 2014-12-08 Interventional | 1 | [1 Refs] | 3 | Antibodies Antibodies, Mon… Polycythemia Polycythemia Ve… Primary Myelofi… Thrombocythemia… Thrombocytosis Myelofibrosis Polycythemia Ve… Post-essential … | Early termination when the drug was no longer made available by the pharmaceutical company due
to unanticipated management and administrative decisions. Early termination when the drug was no longer made available by the pharmaceutical company due to unanticipated management and administrative decisions. Limited patient data (2 evaluable patients), a dose accumulation ratio cannot be determined. | ||
| NCT01226992 Details | 2014-12-08 Interventional | 2/3 | 81 | Vancomycin Clostridium Inf… Communicable Di… Infections Recurrence Laboratory Conf… Recurrent Clost… | Unavailable study resources - | |||
| NCT00095316 Details | 2014-12-05 Interventional | 3 | - | Caspofungin Candidiasis | - - | |||
| NCT02028910 Details | 2014-12-04 Interventional | 3 | 20 | Ondansetron Gastroenteritis Vomiting | - - | |||
| NCT00516399 Details | 2014-12-04 Interventional | 3 | 78 | Natamycin Ophthalmic Solu… Povidone Povidone-Iodine Corneal Ulcer Keratitis Fungal Keratiti… | The DSMC decided it appeared futile to attempt to demonstrate non-inferiority of
povidone-iodine to Natamycin. - | |||
| NCT01666431 Details | 2014-12-03 Interventional | 2 | 10 | Lapatinib Carcinoma Carcinoma, Squa… Squamous Cell C… | - - | |||
| NCT01164046 2009-015336-15 Details | 2014-12-03 Interventional | 3 | 56 | Acenocoumarol Bemiparin Certoparin Dalteparin Enoxaparin Heparin Heparin, Low-Mo… Nadroparin Phenprocoumon Reviparin Tinzaparin Vitamin K Warfarin Embolism Pulmonary Embol… Thromboembolism Thrombosis Venous Thromboe… Venous Thrombos… Neoplasms | Due to slow inclusion of patients - | |||
| NCT00570960 Details | 2014-12-03 Interventional | 4 | 8 | Dextrans Peritonitis Spontaneous Bac… | drug product became unavilable The study was terminated early because the manufacturer of Dextran 70 ceased all production of the study drug approximately 10 months into the study. It was felt by the principle investigator that continuation of the study was impossible. | |||
| NCT02062892 Details | 2014-12-02 Interventional | 4 | 0 | Everolimus Sirolimus Kidney Transpla… | Patients meeting the inclusion/ exclusion criteria did not agree to participate. It became
obvious that recruitment goals could not be met. - |